NCT02200718尚未招募1 期
A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- The primary clinical endpoints are comparisons of MRI & WBC measurements between the treatment groups
研究概览
简要总结
A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety & efficacy
详细描述
A Multi-Center Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety & efficacy 12 subjects with pediatric MS
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 5 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ages Eligible for Study: 5 Years to 17 Years
- •Genders Eligible for Study: Both
- •Accepts Healthy Volunteers: No Criteria
- •Subject is between 5 and 17 years of age, inclusive
- •Clinically diagnosed Pediatric MS
- •Definite Pediatric MS by the revised McDonald criteria (2005) (Appendix A), with a pediatric MS course
- •Expanded Disability Status Scale (EDSS) <= score 6.5 (Appendix B) Two or more documented clinical relapses of MS in the preceding 24 months OR one documented clinical relapse of MS in the preceding 12 months prior to screening
- •Laboratory values within the following limits:
- •Creatinine 1 . 5 x high normal
- •Hemoglobin
排除标准
- •Subjects currently prescribed Campath or Lemtrada
结局指标
主要结局
The primary clinical endpoints are comparisons of MRI & WBC measurements between the treatment groups
时间窗: 26 Weeks
The primary objective is to compare between treatment groups the cumulative number of new gadolinium enhancing (Gd+) lesions on brain MRI \& to compare the increases of WBC white blood cell counts in subjects in the treatment groups with Pediatric MS
次要结局
- A Secondary clinical endpoint is the measurement of FOXP3+ expression(26 Weeks)
- A Secondary clinical endpoint is the measurment of EDSS scores(26 Weeks)
- A Secondary clinical endpoint is the measurement of clinical relapses(26 Weeks)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple SclerosisMultiple SclerosisEUCTR2006-003384-30-SKThe Immune Response Corporation200
Unknown
2 期
A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple SclerosisSecondary Progress Multiple SclerosisMultiple SclerosisNCT02057159Immune Response BioPharma, Inc.200
已完成
1 期
A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical TrialMultiple SclerosisNCT02618902University Hospital, Antwerp9
Unknown
2 期
A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple SclerosisMultiple SclerosisNCT02149706Immune Response BioPharma, Inc.150
已完成
1 期
Safety Study of Multiple Peptide Vaccine to Esophageal CancerEsophageal CancerNCT00561275Japanese Foundation for Cancer Research6